Citadel Advisors’s Acorda Therapeutics ACOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-723
| Closed | -$28.4K | – | 15009 |
|
|
2021
Q4 | $35K | Buy |
+723
| New | +$49.8K | ﹤0.01% | 13418 |
|
|
2021
Q3 | – | Sell |
-2,233
| Closed | -$185K | – | 14978 |
|
|
2021
Q2 | $213K | Buy |
+2,233
| New | +$195K | ﹤0.01% | 12024 |
|
|
2020
Q4 | – | Sell |
-1,106
| Closed | -$102K | – | 11721 |
|
|
2020
Q3 | $68K | Buy |
1,106
+967
| +696% | +$72.9K | ﹤0.01% | 9477 |
|
|
2020
Q2 | $12K | Sell |
139
-731
| -84% | -$77.3K | ﹤0.01% | 9618 |
|
|
2020
Q1 | $97K | Buy |
870
+388
| +80% | +$76.4K | ﹤0.01% | 8654 |
|
|
2019
Q4 | $118K | Buy |
+482
| New | +$122K | ﹤0.01% | 8486 |
|
|
2019
Q3 | – | Sell |
-3,164
| Closed | -$1.72M | – | 9931 |
|
|
2019
Q2 | $2.91M | Buy |
3,164
+76
| +2% | +$93.4K | ﹤0.01% | 3904 |
|
|
2019
Q1 | $4.93M | Buy |
3,088
+876
| +40% | +$1.58M | ﹤0.01% | 3023 |
|
|
2018
Q4 | $4.14M | Buy |
+2,212
| New | +$4.81M | ﹤0.01% | 3051 |
|
|
2017
Q4 | – | Sell |
-109
| Closed | -$310K | – | 8586 |
|
|
2017
Q3 | $310K | Sell |
109
-7,713
| -99% | -$20.3M | ﹤0.01% | 6020 |
|
|
2017
Q2 | $18.5M | Buy |
7,822
+5,122
| +190% | +$10.1M | 0.02% | 1045 |
|
|
2017
Q1 | $6.8M | Buy |
2,700
+2,374
| +728% | +$6.83M | 0.01% | 1740 |
|
|
2016
Q4 | $737K | Sell |
326
-4,544
| -93% | -$10.8M | ﹤0.01% | 4308 |
|
|
2016
Q3 | $12.2M | Buy |
4,870
+3,841
| +373% | +$11.5M | 0.01% | 1202 |
|
|
2016
Q2 | $3.15M | Buy |
1,029
+824
| +402% | +$2.68M | ﹤0.01% | 2260 |
|
|
2016
Q1 | $649K | Buy |
205
+174
| +561% | +$722K | ﹤0.01% | 4050 |
|
|
2015
Q4 | $158K | Sell |
31
-111
| -78% | -$485K | ﹤0.01% | 6139 |
|
|
2015
Q3 | $450K | Buy |
+142
| New | +$551K | ﹤0.01% | 4950 |
|
|
2015
Q2 | – | Sell |
-160
| Closed | -$618K | – | 9193 |
|
|
2015
Q1 | $638K | Buy |
160
+40
| +33% | +$183K | ﹤0.01% | 4554 |
|
|
2014
Q4 | $586K | Sell |
120
-755
| -86% | -$3.24M | ﹤0.01% | 4492 |
|
|
2014
Q3 | $3.56M | Sell |
875
-5,609
| -87% | -$21M | ﹤0.01% | 2298 |
|
|
2014
Q2 | $26.2M | Buy |
6,484
+4,713
| +266% | +$19.2M | 0.03% | 668 |
|
|
2014
Q1 | $8.06M | Sell |
1,771
-748
| -30% | -$3.02M | 0.01% | 1412 |
|
|
2013
Q4 | $8.83M | Buy |
2,519
+1,671
| +197% | +$6.51M | 0.01% | 1290 |
|
|
2013
Q3 | $3.49M | Buy |
848
+418
| +97% | +$1.8M | 0.01% | 1885 |
|
|
2013
Q2 | $1.7M | Buy |
+430
| New | +$1.77M | ﹤0.01% | 2650 |
|
Other funds holding ACOR
DKCM
Citadel Advisors's ACOR Position: Q1 2022 in Review
Citadel Advisors sold out of Acorda Therapeutics (ACOR) in Q1 2022, closing a stake of 723 shares — an estimated $28.4K sold.
Citadel Advisors first reported a position in ACOR in Q2 2013 and held it in 26 quarters. The position peaked at $26.2M in Q2 2014. 31 funds tracked by Wall St. Rank hold ACOR as of Q1 2022.
- Citadel Advisors reported no remaining Acorda Therapeutics position as of Q1 2022 after selling out during the quarter.
- Citadel Advisors sold 723 Acorda Therapeutics shares in Q1 2022, an estimated $28.4K.
- Citadel Advisors first reported a position in Acorda Therapeutics in Q2 2013 and held it in 26 quarters.
- Citadel Advisors's Acorda Therapeutics position peaked at $26.2M in Q2 2014.
- 31 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2022.
Based on Citadel Advisors's 13F filing for Q1 2022, filed 16 May 2022.